Rolling coverage of the latest economic and financial news
The Financial Times have also scrutinised Anthropic’s IPO prospectus, and report that the Claude maker also provided investors with a clearer picture of the challenging economics of building state of the art AI models.
Anthropic said it plans to spend $518bn on cloud, computing and infrastructure obligations in the coming years to support its rapid growth.
The AI lab’s backers are confident Anthropic can list at a valuation of over $2tn, more than double the level achieved in its last funding round in May and beyond the $1.78tn achieved by Elon Musk’s SpaceX in June. They point to its extraordinary growth rate to justify their bullishness.
“A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumour types with combinations alongside next-generation immunotherapies.
Bispecifics targeting PD-1 and VEGF are rapidly advancing in development and have the potential to improve on current immunotherapies, particularly in lung, breast and gastrointestinal cancers. This opportunity to combine ivonescimab with AstraZeneca’s ADC portfolio, including with Sone-Ve, could enable new regimens that raise the bar for patients with cancer across the treatment landscape.”
Continue reading...